Camilla Cunningham News Today

Investegate announcements from Hikma Pharmaceutical, Notice of Results

Investegate announcements from Hikma Pharmaceutical, Trading Statement

Investegate announcements from Hikma Pharmaceutical, Correction statement re Opiant

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

Camilla Cunningham  + 44 (0) 7464 982426   About Hikma Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moodys) Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, weve been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the...

About Hikma Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI: 549300BNS685UXH4JI75) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moodys)   Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, weve been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with...

Hikma launches generic Advair Diskus® following FDA approval News provided by Share this article Share this article LONDON, Dec. 17, 2020 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has received FDA approval for and launched its generic version of GlaxoSmithKlines Advair Diskus ®1 (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US. Hikma worked with Vectura Group, a UK ...

  London, 17 December  2020   - Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, annou nces it has received FDA approval for and launched its generic version of GlaxoSmithKlines Advair Diskus ®1 (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US.   Hikma worked with Vectura Group, a UK based provider of innovative inhaler drug delivery soluti...